Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer
Megadott ok: Enrollment Goal Met
Key facts
- Where
- Atlanta, Chicago, Houston és Salt Lake City, Egyesült ÁllamokSee the 5 sites
- Phase
- 1/2. fázis
Where in Egyesült Államok
- Winship Cancer Institute, Emory UniversityAtlanta, Egyesült ÁllamokNo longer taking part
- University of ChicagoChicago, Egyesült ÁllamokNo longer taking part
- University of Illinois at Chicago (UIC)Chicago, Egyesült ÁllamokNo longer taking part
- MD Anderson Cancer CenterHouston, Egyesült ÁllamokNo longer taking part
- Huntsman Cancer InstituteSalt Lake City, Egyesült ÁllamokNo longer taking part
Trial details
- Who runs it
- University of Chicago
- Trial code
- NCT04683653
- Record updated
- 2026. szeptember 10.
- Original description
This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to ensure that the total radiation dose they receive is still effective and similar to the radiation dose they would receive if they were not participating in this study (standard treatment).Read full original descriptionShow less
RT-PACE: Phase I/II Study of Adjuvant Whole Pelvic Hypofractionated Radiotherapy for Non-Metastatic Cervical and Endometrial Cancer
This study will investigate if a shorter treatment course (known as "hypofractionation") for pelvic radiation is safe for women with endometrial cancer. Doctors leading the study will also determine the safest and most tolerable dose of shortened radiation (hypofractionation) used to treat women in this study. Because this study will shorten the radiation course typically used to treat endometrial cancer, each daily treatment given to women in this study will be slightly higher than normal to ensure that the total radiation dose they receive is still effective and similar to the radiation dose they would receive if they were not participating in this study (standard treatment).
Inclusion: Diagnosis of primary cervical cancer or uterine cancer of any histology; Age ≥ 18 years; Non-metastatic disease according to the International Federation of Gynecology and Obstetrics (FIGO); Must have been treated with definitive intent, including standard-of-care hysterectomy, without any gross residual disease post-operatively. Nodal dissection is not required, but if it is not performed, then diagnostic imaging to confirm absence of gross pelvic or para-aortic disease should be obtained pre- or post-operatively; Recommended to undergo whole pelvic radiotherapy without concurrent chemotherapy or para-aortic radiation. Chemotherapy before or after radiotherapy is acceptable; Eastern Cooperative Oncology Group (ECOG) PS≤ 2; Able to provide informed consent and willingness to sign an approved consent form.
Exclusion: Concurrent (or other) chemotherapy occurring at the time of study; History of small bowel obstruction, inflammatory bowel disease, irritable bowel syndrome, connective tissue disorder requiring ongoing active medical management, or prior radiation therapy directed to the pelvis; Unresolved grade 2 or higher chemotherapy-associated diarrhea or abdominopelvic pain requiring medication prior to the initiation of radiation; Recommendation to undergo para-aortic nodal irradiation; Distant metastases as determined clinically or radiographically based upon standard-of-care work-up for endometrial cancer; Gross residual disease (cancer cells that remain after attempts to remove the cancer have been made) post-operatively and/or at the time of radiation based upon pre-op or post-op imaging, intra-operative findings, and gynecologic oncologists' judgment.